GILD Biotech Monday, June 8, 2026 0.00 Neutral

Merck And Gilead Discontinue Phase 3 KEYNOTE-D46/EVOKE-03 Trial After Trodelvy–KEYTRUDA Combination Fails To Achieve Statistically Significant Progression-Free Survival Benefit In First-Line Metastatic NSCLC

Merck And Gilead Discontinue Phase 3 KEYNOTE-D46/EVOKE-03 Trial After Trodelvy–KEYTRUDA Combination Fails To Achieve Statistically Significant Progression-Free Survival Benefit In First-Line Metastatic NSCLC

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day